If you have been reading about reverse-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-24. Numbers and descriptions here follow the published literature rather than marketing material.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
| Property | Value | Notes |
|---|---|---|
| Typical purity report | 95% or higher by HPLC | Area percentage at 214 nm |
| Identity confirmation | Mass spectrometry | Electrospray or MALDI |
| Powder storage | -20 C, desiccated | Protect from light |
| Solution storage | 2-8 C short term | Freeze aliquots for longer |
| Quality document | Certificate of analysis | States method and value |
Lyophilised material kept dry at minus 20 degrees Celsius or colder is the most stable form, and suppliers commonly state a shelf life of two years or more under those conditions. Once dissolved, degradation accelerates through hydrolysis and deamidation, particularly at alkaline pH or elevated temperature. Working solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. The choice of reconstitution solvent affects both stability and the ionic strength of the final preparation.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
In North Africa, Rhodesians in the 11th Hussars, 2nd Leicesters, 1st Cheshires and other regiments contributed to Operation Compass between December 1940 and February 1941 as part of the Western Desert Force under Major-General Richard O'Connor, fighting at Sidi Barrani, Bardia, Beda Fomm and elsewhere. This offensive was extremely successful, with the Allies suffering very few casualties—around 700 killed and 2,300 wounded and missing—while capturing the strategic port Tobruk, over 100,000 Italian soldiers and most of Cyrenaica. The Germans reacted by despatching the Afrika Korps under Erwin Rommel to shore up the Italian forces. Rommel led a strong counter-offensive in March–April 1941 that forced a general Allied withdrawal towards Egypt. German and Italian forces surrounded Tobruk but failed to take the largely Australian-garrisoned city, leading to the lengthy Siege of Tobruk. The Rhodesian contingents in the 11th Hussars, Leicesters, Buffs, Argylls, Royal Northumberland Fusiliers, Durham Light Infantry and Sherwood Foresters were transferred en masse to Kenya in February 1941 to join the new Southern Rhodesian Reconnaissance Regiment, which served in East Africa over the following year. The Rhodesians in the 1st Cheshires moved with that regiment to Malta the same month. The Rhodesian Signallers were withdrawn to Cairo to form a section handling high-speed communications between Middle East Command and General Headquarters in England.
Mycoplasma pneumoniae Chlamydia pneumoniae Hepatitis B virus (HBV) Parvovirus B19 Adenovirus (ADV) Respiratory syncytial virus (RSV) The immune cell involvement in polymyalgia rheumatica includes the activation of dendritic cells and monocytes/macrophages, leading to inflammation in the synovium and bursae of the shoulder and hip girdles which is primarily mediated by the innate immune system. There is an altered balance between Th17 and Treg cells, with increased IL-6 levels driving Th17 cell activation. Disturbed B cell distribution and function are also observed, with a decrease in circulating B cells that recover after steroid treatment. Additionally, systemic activation of circulating monocytes is associated with increased IL-6 and IL-1 beta production. Associations of uncertain significance with multiple types of TNF have also been found. Despite the severe pain associated with the condition in multiple muscle groups, as well as the signs of systemic inflammation, muscle biopsies have found no signs of localized inflammation in muscle tissue in patients with PMR. Electromyography studies also typically turn up normal. The only locations known definitively to be inflamed in PMR are the synovial membranes and bursae of joints. Persons having the HLA-DR4 type of human leucocyte antigen appear to have a higher risk of PMR.
X-linked intellectual disability refers to medical disorders associated with X-linked recessive inheritance that result in intellectual disability. As with most X-linked disorders, males are more heavily affected than females. Females with one affected X chromosome and one normal X chromosome tend to have milder symptoms. Unlike many other types of intellectual disability, the genetics of these conditions are relatively well understood. It has been estimated there are ~200 genes involved in this syndrome; of these ~100 have been identified. Many of these genes are found on the short 'p' arm of the chromosome, and duplications at Xp11.2 are associated with the syndromic form of the condition. X-linked intellectual disability accounts for ~16% of all cases of intellectual disability in males.
Sources: en.wikipedia.org
== Structural topology == The topology of a β-sheet describes the order of hydrogen-bonded β-strands along the backbone. For example, the flavodoxin fold has a five-stranded, parallel β-sheet with topology 21345; thus, the edge strands are β-strand 2 and β-strand 5 along the backbone. Spelled out explicitly, β-strand 2 is H-bonded to β-strand 1, which is H-bonded to β-strand 3, which is H-bonded to β-strand 4, which is H-bonded to β-strand 5, the other edge strand. In the same system, the Greek key motif described above has a 4123 topology. The secondary structure of a β-sheet can be described roughly by giving the number of strands, their topology, and whether their hydrogen bonds are parallel or antiparallel. β-sheets can be open, meaning that they have two edge strands (as in the flavodoxin fold or the immunoglobulin fold) or they can be closed β-barrels (such as the TIM barrel). β-Barrels are often described by their stagger or shear. Some open β-sheets are very curved and fold over on themselves (as in the SH3 domain) or form horseshoe shapes (as in the ribonuclease inhibitor). Open β-sheets can assemble face-to-face (such as the β-propeller domain or immunoglobulin fold) or edge-to-edge, forming one big β-sheet.
Slavery in early medieval Europe was so common that the Catholic Church repeatedly prohibited it, or at least the export of Christian slaves to non-Christian lands, as for example at the Council of Koblenz (922), the Council of London (1102) (which aimed mainly at the sale of English slaves to Ireland) and the Council of Armagh (1171). Serfdom, on the contrary, was widely accepted. In 1452, Pope Nicholas V issued the papal bull Dum Diversas, granting the kings of Spain and Portugal the right to reduce any "Saracens (Muslims), pagans and any other unbelievers" to perpetual slavery, legitimizing the slave trade as a result of war. The approval of slavery under these conditions was reaffirmed and extended in his Romanus Pontifex bull of 1455. Large-scale trading in slaves was mainly confined to the South and East of early medieval Europe: the Byzantine Empire and the Muslim world were the destinations, while pagan Central and Eastern Europe (along with the Caucasus and Tartary) were important sources. Viking, Arab, Greek, and Radhanite Jewish merchants were all involved in the slave trade during the Early Middle Ages. The trade in European slaves reached a peak in the 10th century following the Zanj Rebellion, which dampened the use of African slaves in the Arab world. In Britain, slavery continued to be practiced following the fall of Rome, while sections of Æthelstan's and Hywel the Good's laws dealt with slaves in medieval England and medieval Wales respectively.
== Risks == As with any procedure, there are risks involved; these include reactions to medicine, problems breathing, bleeding, and infection. Infection is reported to occur in less than 1% of cases and is curable with antibiotics. Overall, patients with a preexisting illness are at a higher risk of getting an infection as opposed to those who are overall healthy.
MS1 is a positive allosteric modulator (PAM) of the μ-opioid receptor (MOR). It was developed from structural modification of the earlier MOR PAM BMS‐986122. The drug has been found to augment the affinity of the MOR agonist levomethadone ((R)-methadone) for the MOR by 7-fold in vitro and to potentiate activation of the MOR by levomethadone by 4-fold in a G protein assay. However, MS1 displays strong probe dependence, and while it potentiates the MOR agonists levomethadone and morphine, it had no effect on the affinity or potency of the MOR agonists DAMGO or endomorphin-1. MS1 shows a preference for β-arrestin recruitment over G protein activation with endomorphin-1 exposure. The drug's actions are reportedly similar to those of BMS-986122, though its unclear if their mechanisms of action are the same. MS1 shows potentiated analgesic effects with opioids in animals. It also did not worsen opioid withdrawal symptoms, respiratory depression, or analgesic tolerance. MS1 and other atypical MOR activators are of potential interest in the development of novel opioid analgesics with reduced adverse effects and misuse potential. MS1 has notably been found to penetrate the blood–brain barrier in animals. The potential of the related MOR PAMs BMS-986121 and BMS-986122 as pharmaceutical drugs has been restricted owing to their complex chemical synthesis. MS1 has a much simpler synthesis in comparison and hence has been regarded as having overcome this limitation. MS1 was first described in the scientific literature by 2015.
Sources: en.wikipedia.org
Purity is usually reported as an HPLC area percentage, most often measured at 214 nm. Identity is confirmed separately by mass spectrometry. A certificate of analysis should state both the method and the observed value.
Dry powder is kept frozen, desiccated, and shielded from light. Dissolved material is aliquoted and frozen to limit freeze-thaw cycles. Short-term refrigerated storage is common for working solutions.
Russia registers it as a prescription nasal product. Most other markets classify it as a research chemical with no approved medical use. Oversight of purity and labeling is consequently minimal in those markets.
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, commonly written as TKPRPGP. It shares the first four residues with tuftsin and carries three prolines in the chain. The proline-rich tail is the main structural feature that separates it from the parent tetrapeptide.